Asia Pac ECM and Index Rebal, Shenton Research

Ke Yan, CFA, FRM

Asia Pac ECM and Index Rebal

Asia Pac IPO & Placement Research, China Biotech

DZT Research

DZT Research is an independent Asia Pacific equity specialist. Our quantitative research covers index rebalancing flows, alongside exchange data analytics accross Asia Pacific. On the equity capital markets side, we focus on Asia Pacific ECM, especially biotech and TMT. Our lead analyst is frequently cited by international media.

Quantitative Analysis

<ul>
<li>We analyzed the latest HK SFC report for aggregate short position as of Nov 14th.</li>
<li>Top short increases and decreases were tabulated for one week and four week period.</li>
<li>We highlight short changes in Xpeng (9868 HK), TraHK HSI ETF (2800 HK).</li>
</ul>


We analyzed the latest HK SFC report for aggregate short position as of Nov 14th.
Top short increases and decreases were tabulated for one week and four week period.
We highlight short changes in Xpeng (9868 HK), TraHK HSI ETF (2800 HK).


Equity Derivatives and Volatility Specialist, Clifton Derivatives

John Ley

Equity Derivatives and Volatility Specialist

Clifton Derivatives

Independent derivative and volatility research firm focusing on events/catalysts, earnings, relative value and cross asset volatility strategies.

Equity Derivatives

<ul>
<li>Broad declines set a cautious tone as only a handful of single stocks avoided losses last week amid rising option volumes.</li>
<li>Market breadth deteriorated sharply, marking the weakest showing of the past year and highlighting the pressure across Hong Kong equities.</li>
<li>We highlight companies reporting next week in what shapes up as a busy week ahead with Baba and Meituan both reporting.</li>
</ul>


Broad declines set a cautious tone as only a handful of single stocks avoided losses last week amid rising option volumes.
Market breadth deteriorated sharply, marking the weakest showing of the past year and highlighting the pressure across Hong Kong equities.
We highlight companies reporting next week in what shapes up as a busy week ahead with Baba and Meituan both reporting.


Hong Kong Single Stock Options Weekly (Nov 17 – 21): Breadth Collapses, Put Volumes Rise

HK/China Equity Long-Short

Osbert Tang, CFA

Equity Capital Markets

CNGR Advanced Material / Equity Capital Markets

<ul>
<li>
<a href="https://www.smartkarma.com/entities/cngr-advanced-material-co-ltd-47ff2856-4dc1-492a-8394-03d69de02ce4" target="_blank" data-smartkarma-citation="entities:45994:1" rel="noopener">CNGR Advanced Material (2579 HK)</a>'s IPO price was fixed at the low end at HK$34.00. However, valuation is inexpensive, and initial price weakness is a long-term opportunity.</li>
<li>Three groups of close peers, including nickel-related companies, mining companies, and lithium/battery companies, trade on average FY26F PER of 21x, vs. CNGR's 12.5x.</li>
<li>By parking it with the steepest HA discount of its peers (26.2%), CNGR will be valued at HK$40.07, as its IPO price implies a massive 37.4% discount.</li>
</ul>



CNGR Advanced Material (2579 HK)'s IPO price was fixed at the low end at HK$34.00. However, valuation is inexpensive, and initial price weakness is a long-term opportunity.
Three groups of close peers, including nickel-related companies, mining companies, and lithium/battery companies, trade on average FY26F PER of 21x, vs. CNGR's 12.5x.
By parking it with the steepest HA discount of its peers (26.2%), CNGR will be valued at HK$40.07, as its IPO price implies a massive 37.4% discount.


CNGR Advanced Material (2579 HK): Opportunity Is Out There

<ul>
<li>We analyse the changes of A-H premium on 160 stocks over the last week. The average A-H premium was 61.1% as of Nov 14th.</li>
<li>The average A-H premium changed by -0.4ppt week-on-week, led by consumer staples, materials, information technology and offset by real estate, energy, utilities.</li>
<li>We highlight weekly changes in A-H premium for Ganfeng Lithium, Baiyunshan Pharma, China Life, CATL, ABC.</li>
</ul>


We analyse the changes of A-H premium on 160 stocks over the last week. The average A-H premium was 61.1% as of Nov 14th.
The average A-H premium changed by -0.4ppt week-on-week, led by consumer staples, materials, information technology and offset by real estate, energy, utilities.
We highlight weekly changes in A-H premium for Ganfeng Lithium, Baiyunshan Pharma, China Life, CATL, ABC.


A-H Premium Weekly (Nov 14th): Ganfeng Lithium, Baiyunshan Pharma, China Life, CATL, ABC

<ul>
<li>We analysed the earning revision of component stocks of CSI 300 in the past month.</li>
<li>We tabulated stocks with the top impact on index's EPS, stocks' EPS revision, and revenue revision.</li>
<li>We highlighted EPS revision on Wuliangye, China Life, SHANGHAI PUDONG DEVELOPMENT BANK, BYD, PING AN INSURANCE, CHONGQING ZHIFEI BIOLOGICAL PRODUCTS, CHINA EASTERN AIRLINES, GUANGZHOU AUTOMOBILE, Ping An Insurance.</li>
</ul>


We analysed the earning revision of component stocks of CSI 300 in the past month.
We tabulated stocks with the top impact on index's EPS, stocks' EPS revision, and revenue revision.
We highlighted EPS revision on Wuliangye, China Life, SHANGHAI PUDONG DEVELOPMENT BANK, BYD, PING AN INSURANCE, CHONGQING ZHIFEI BIOLOGICAL PRODUCTS, CHINA EASTERN AIRLINES, GUANGZHOU AUTOMOBILE, Ping An Insurance.


CSI 300 Index Earning Revision (Oct): Wuliangye, China Life, SPDB, BYD

China

Ganfeng Lithium is a global leader in the lithium industry, specializing in the production and sales of lithium products and lithium batteries. Its business spans the entire lithium value chain, including upstream lithium resource development, midstream lithium refining and metal smelting, and downstream lithium battery manufacturing and recycling. The company's products, such as lithium salts and batteries, are widely used in electric vehicles, energy storage systems, consumer electronics, chemicals, and pharmaceuticals. Ganfeng Lithium was founded in 2000 and is headquartered in Xinyu City, Jiangxi Province, China.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Ganfeng Lithium (1772 HK)

HK Short Interest Weekly: Xpeng

We analyzed the latest HK SFC report for aggregate short position as of Nov 14th and highlight short interest changes in Xpeng, TraHK HSI ETF.

Ke Yan, CFA, FRM

Hong Kong Single Stock Options Weekly (Nov 17 – 21): Breadth Collapses, Put Volumes Rise

Hong Kong single stocks faced sharp declines and the weakest breadth of the year, while option flows strengthened and implied vols softened.

John Ley

CNGR Advanced Material (2579 HK): Opportunity Is Out There

CNGR Advanced Material's IPO price fixed at low end due to lukewarm response, but valuation seen as inexpensive compared to close peers in nickel,...

Osbert Tang, CFA

A-H Premium Weekly (Nov 14th): Ganfeng Lithium, Baiyunshan Pharma, China Life, CATL, ABC

We analyzed A-H premium changes in the past week and highlight A-H premium changes for Ganfeng Lithium, Baiyunshan Pharma, China Life, CATL, ABC.

Ke Yan, CFA, FRM

CSI 300 Index Earning Revision (Oct): Wuliangye, China Life, SPDB, BYD

We analyzed CSI 300's consensus for Oct 2025 and highlighted changes of EPS in Wuliangye (000858 CH), China Life (601628 CH), SHANGHAI PUDONG...

Ke Yan, CFA, FRM

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

HK Short Interest Weekly: Xpeng

We analyzed the latest HK SFC report for aggregate short position as of Nov 14th and highlight short interest changes in Xpeng, TraHK HSI ETF.

Ke Yan, CFA, FRM

Hong Kong Single Stock Options Weekly (Nov 17 – 21): Breadth Collapses, Put Volumes Rise

Hong Kong single stocks faced sharp declines and the weakest breadth of the year, while option flows strengthened and implied vols softened.

John Ley

CNGR Advanced Material (2579 HK): Opportunity Is Out There

​CNGR Advanced Material's IPO price fixed at low end due to lukewarm response, but valuation seen as inexpensive compared to close peers in nickel,...

Osbert Tang, CFA

A-H Premium Weekly (Nov 14th): Ganfeng Lithium, Baiyunshan Pharma, China Life, CATL, ABC

We analyzed A-H premium changes in the past week and highlight A-H premium changes for Ganfeng Lithium, Baiyunshan Pharma, China Life, CATL, ABC.

Ke Yan, CFA, FRM

CSI 300 Index Earning Revision (Oct): Wuliangye, China Life, SPDB, BYD

We analyzed CSI 300's consensus for Oct 2025 and highlighted changes of EPS in Wuliangye (000858 CH), China Life (601628 CH), SHANGHAI PUDONG...

Ke Yan, CFA, FRM

CNGR Advanced Material's IPO price fixed at low end due to lukewarm response, but valuation seen as inexpensive compared to close peers in nickel,...